American Century Companies Inc. raised its stake in Amedisys Inc (NASDAQ:AMED) by 6.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,787,136 shares of the health services provider’s stock after purchasing an additional 115,456 shares during the quarter. American Century Companies Inc. owned approximately 0.05% of Amedisys worth $94,200,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. UBS Asset Management Americas Inc. grew its stake in Amedisys by 23.9% in the second quarter. UBS Asset Management Americas Inc. now owns 14,572 shares of the health services provider’s stock valued at $915,000 after purchasing an additional 2,812 shares in the last quarter. Wells Fargo & Company MN grew its stake in Amedisys by 29.7% in the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after purchasing an additional 339,825 shares in the last quarter. Copper Rock Capital Partners LLC boosted its stake in shares of Amedisys by 3.6% during the 4th quarter. Copper Rock Capital Partners LLC now owns 596,014 shares of the health services provider’s stock worth $31,386,000 after acquiring an additional 20,699 shares during the period. Castleark Management LLC bought a new position in shares of Amedisys during the 2nd quarter worth approximately $3,674,000. Finally, Sterling Capital Management LLC boosted its stake in shares of Amedisys by 15.8% during the 3rd quarter. Sterling Capital Management LLC now owns 16,654 shares of the health services provider’s stock worth $932,000 after acquiring an additional 2,268 shares during the period. Hedge funds and other institutional investors own 94.97% of the company’s stock.
Several research analysts have recently commented on AMED shares. Craig Hallum reiterated a “buy” rating and set a $68.00 target price (up from $55.00) on shares of Amedisys in a research note on Thursday, November 9th. SunTrust Banks reiterated a “buy” rating and set a $70.00 target price on shares of Amedisys in a research note on Friday, November 10th. Mizuho reiterated a “buy” rating and set a $65.00 target price (up from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Benchmark upgraded Amedisys from a “hold” rating to a “buy” rating and set a $56.00 target price for the company in a research note on Thursday, November 2nd. Finally, Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a research note on Friday, January 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. Amedisys presently has an average rating of “Hold” and an average price target of $60.64.
COPYRIGHT VIOLATION WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2018/02/10/american-century-companies-inc-has-94-20-million-holdings-in-amedisys-inc-amed.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.